Blaze Vector Production
Forge provides Blaze Vector Production to help researchers and gene therapy developers access turnkey, scalable, research-grade vector production at 1-40L without a long-term commitment.
Starting with The End In Mind
Blaze leverages Forge’s proprietary, commercially viable technologies, including our HEK293 suspension Ignition Cells™, pEMBR™ 2.0 Ad Helper Plasmid, and Modified Rep/Caps to enable efficient and scalable AAV production, from research through cGMP manufacturing. Developers use Blaze for:

Generating Research-Grade AAV

Identifying lead therapeutic candidates

Understanding the manufacturability of their vector

Seamless scale up to cGMP

Process
How Blaze Works
Produce research-grade AAV for early-stage discovery work like proof-of-concept studies and evaluating vector manufacturability.
-1024x576.png)
Ready for growth
Post-Research Support
Forge provides the same expert guidance and support for your program as it moves toward clinical production. With your proof-of-concept in place, we continue to support your journey with integrated AAV manufacturing services tailored to your next phase.

Power Your Discovery with Blaze
Connect with our client development team to get started with Blaze.
Frequently Asked Questions
Does Forge Biologics provide AAV CRO services?
Forge Biologics is a CDMO (Contract Development and Manufacturing Organization) and does not provide CRO services. We specialize in AAV manufacturing, offering research-grade production, process development, GMP manufacturing, and integrated support services such as molecular development, analytics, and regulatory consultation. While we don’t provide traditional CRO services—like preclinical or clinical trial management—we work closely with clients to support their manufacturing strategy throughout the development lifecycle and maintain preferred partnerships with CROs that we can connect our clients to as needed.
How quickly can Forge deliver a GMP batch?
Timelines for GMP batch delivery are highly dependent on the specifics of your program, including vector design, process readiness, and scope of work. By partnering with Forge and leveraging our proprietary platform and integrated services—such as in-house analytics and plasmid production—developers may accelerate timelines to GMP manufacturing by up to 30% compared to full process development. Connect with our Client Development team to discuss your program and receive a more detailed scope of work based on your program needs.
The Latest in AAV Manufacturing
-
Affinia Therapeutics and Forge Biologics Announce AAV cGMP Manufacturing Partnership
“We’re proud to support Affinia’s vision of bringing hope to patients affected by cardiomyopathy through their innovative gene therapy.”
-
Forge Biologics Announces the FUEL™ AAV Manufacturing Platform
FUEL™ platform can achieve a 2-6x increase in productivity compared to industry standard, and includes pEMBR 2.0™ Ad helper and modified rep/cap plasmids.
-
Forge Biologics Announces Planned CEO Succession
John Maslowski, Chief Commercial Officer, to succeed Dr. Timothy Miller as President and CEO. “It’s an exciting time at Forge.”
-
Muscular Dystrophy Association and Forge Biologics Announce AAV Development and Manufacturing Partnership
“Forge has proven to be a trusted partner to gene therapy innovators, advancing many critical programs for rare diseases” Sharon Hesterlee, Ph.D., CRO at the MDA.